Biotech IPOs: what are we AIMing for?

Join the BIA, Stifel and colleagues from the investment sector at this informal networking breakfast on 28 September. Open to investors, fund managers and the finance community only.

This panel event will discuss the performance of AIM, NASDAQ and other stock exchanges in the financing of UK biotech companies. Which exchanges allow UK companies to raise the most cash, achieve greatest liquidity and attract more follow on funding, and why? In recent years the biggest UK biotech IPOs have been on NASDAQ, is AIM just in a slump or is there a fundamental problem that the UK needs to address? And what impact will recent changes to the Hong Kong exchange rules, which now allow unprofitable biotechs to list there, have on the UK ecosystem?   

Please note, this event is open to investors, fund managers and the finance community only.

Agenda

8.00 - 8.30 Registration, networking breakfast

8.30 - 8.40 BIA finance update

8.40 - 9.30 Panel discussion

9.30 - 10.00 Networking

Speakers

Steve Bates

Chief Executive Officer

BIA

Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.

A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.

Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.

Neil Clark

Chief Executive Officer

Destiny Pharma

Neil Clark, CEO, has broad experience within private and public biotechnology and healthcare companies at CEO and CFO level. Neil has been successful in completing two previous London listings, a SEC acquisition and several secondary financings. Neil has also been involved in identifying and completing licensing deals with pharma and biotech companies and managing international business development projects in healthcare.

James Clark

Head of Tech and Lifesciences, Primary Markets

London Stock Exchange

James joined the London Stock Exchange in January 2016 in Business Development with a sector focus on the Technology and Lifesciences industries. James brings this sector focus to help startups and investors by demolishing the myths around public markets. James is based in London but integrates with colleagues across Europe, Israel, Asia and the rest of the world.
Over nearly 20 years, James as developed a broad range of experience in marketing, policy and deep industry knowledge around venture funding and tech startups. In recent years, as a “one man think tank” at the British Venture Capital Association, James published policy research into the role of technology and innovation. His three major research papers Tech Country, The Missing Piece, and VC Evolved, looked at how early stage entrepreneurship interacts with sources of growth funding. Alongside this work, James is a member of the Tech Nation Future Fifty judging panel, is a judge for Diversity UK’s 100 Asian Tech Stars, as well as the founder of TLA Triage, a free advice service for startups under the auspices of Tech London Advocates.
James has an MBA from Cass Business School in London and a BA in Political Science from Macquarie University in Sydney.

Venue

Stifel

150 Cheapside 

London

EC2V 6ET

BIA Annual Supporters

Register